VIDEO: Positive trial results on selective estrogen receptor degrader 'exciting'
Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about a recent study on elacestrant.
Results from the EMERALD trial — which assessed elacestrant (Menarini Group/Radius Health) in patients with ER-positive, HER2-negative advanced or metastatic breast cancer — were presented at this year’s San Antonio Breast Cancer Symposium.
Krop explained that the study showed superior efficacy with elacestrant, a selective estrogen receptor degrader (SERD), compared with standard-of-care endocrine therapy.
He said that “having this first randomized trial being a positive trial is exciting,” not just for elacestrant itself, “but the fact that there’s a number of other SERDs in development is good news for patients since we haven’t had a new endocrine therapy in 20-plus years.”
Bardia A, et al. Abstract GS2-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.